Gene · 4709
NDUFB3: NADH:ubiquinone oxidoreductase subunit B3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. NDUFB3: NADH:ubiquinone oxidoreductase subunit B3. Genes, record 4709. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4709
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O43676 | NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 | 98 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents27
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 54945 | O43676 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 54946 | O43676 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 54948 | O43676 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 953 | O43676 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2810 | O43676 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2810 | O43676 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 953 | O43676 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 55117 | O43676 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 55119 | O43676 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 55120 | O43676 | Espacenet |
1 to 10 of 27
See all 27 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ME-344 | CHEMBL5314386 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN | CHEMBL1431 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN HYDROCHLORIDE | CHEMBL1703 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| NV-128 | CHEMBL3545135 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
Trials1,218
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604870 | METFORMIN | PHASE2 | ClinicalTrials.gov | |
| NCT07604779 | METFORMIN | ClinicalTrials.gov | ||
| NCT07603505 | METFORMIN | PHASE1 | ClinicalTrials.gov | |
| NCT07589387 | METFORMIN | ClinicalTrials.gov | ||
| NCT07588932 | METFORMIN | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07585396 | METFORMIN | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07582471 | METFORMIN | ClinicalTrials.gov | ||
| NCT07520110 | METFORMIN | PHASE3 | ClinicalTrials.gov | |
| NCT07516821 | METFORMIN | ClinicalTrials.gov | ||
| NCT07513480 | METFORMIN | ClinicalTrials.gov |
1 to 10 of 1,218
See all 1,218 trialsNIH grants2,271
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | NDUFB3 papers | Newest fiscal year |
|---|---|---|---|
| ZIAAI005022 | Antibody Neutralization Mechanisms | 19 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 18 | 2025 |
| R01DK045776 | B12 Trafficking and Inherited Defects | 17 | 2025 |
| ZIAAI005024 | Design Of Immunogens | 17 | 2025 |
| ZIAAI005095 | HIV Neutralizing Antibodies: Isolation, characterization, and interaction with viral variants | 14 | 2025 |
| P01AI100148 | Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies | 13 | 2025 |
| P30AI027767 | UAB Center for AIDS Research (CFAR) | 13 | 2025 |
| ZIAAI001090 | Mechanisms of Effective Humoral Immune Responses to HIV-1 | 12 | 2025 |
| P30AI064518 | Center for AIDS Research | 11 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
1 to 10 of 2,271Source NIH's project files
See all 2,271 nih grantsPapers2,987
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Vitamin B12 absorption and factors associated with the response to long-term oral B12 supplementation: a secondary analysis of data from a B12-deficient Indian rural community. | Eur J Clin Nutr | 2026 | 42768083 | PubTator, text mining | PubMed |
| The impact of vitamin B12 deficiency on urinary profile of de novo purine synthesis intermediates: consequences of the methylfolate trap. | Nucleosides Nucleotides Nucleic Acids | 2026 | 42343592 | PubTator, text mining | PubMed |
| Elevated B12/CRP Index as a Simple Prognostic Indicator in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Targeted Therapy. | Biomedicines | 2026 | 42193456 | PubTator, text mining | PubMed |
| Shared gene signatures between rheumatoid arthritis and Sjögren's syndrome. | Am J Clin Exp Immunol | 2026 | 42179742 | PubTator, text mining | PubMed |
| A Multimodal Approach for Study Diagnosis of MCI and Dementia in the Successful Aging After Elective Surgery (SAGES) Cohort. | Am J Geriatr Psychiatry Open Sci Educ Pract | 2026 | 42137496 | PubTator, text mining | PubMed |
| The acute presentation of nitrous oxide-induced vitamin B-12 deficiency in a postoperative lumbar discectomy patient: illustrative case. | J Neurosurg Case Lessons | 2026 | 41911606 | PubTator, text mining | PubMed |
| Identification and Verification of Mitochondria-Related Diagnostic Markers of Spinal Cord Injury by WGCNA and Machine Learning. | Behav Neurol | 2026 | 41810912 | PubTator, text mining | PubMed |
| Coherent control of (non-)Hermitian mode coupling: tunable chirality and exceptional point dynamics in photonic microresonators. | Light Sci Appl | 2026 | 41792106 | PubTator, text mining | PubMed |
| Vitamin deficiencies and Alzheimer's disease: evidence and implications for supplementation. | Front Nutr | 2026 | 41769656 | PubTator, text mining | PubMed |
| Sensitising PDAC to Gemcitabine by Suppressing NF-κB Pathway and Enhancing Apoptosis. | Pharmaceuticals (Basel) | 2026 | 41754784 | PubTator, text mining | PubMed |
1 to 10 of 2,987
See all 2,987 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4709
GET https://conductscience.org/api/genes/v1/4709/patents?page=2